| PAD Consequences |
2 |
| Consequences of Critical Limb Ischemia and First Stroke. |
3 |
| Percentage of Patients With Intermittent Claudication. |
3 |
| Cause of Death in PAD. |
4 |
| Five-Year All Cause Mortality for Selected Diseases |
5 |
| Ten-Year Mortality for PAD by Disease Severity Compared
With Survivors of First Heart Attack |
5 |
| Percentage of PAD Patients With CAD or CVD |
6 |
| Five-Year Mortality and Incidence of Non-Fatal MI or Stroke |
6 |
| Six-Year Cardiovascular Morbidity Increases With Severity of PAD |
7 |
| Six-Year Mortality Increases With Severity of PAD |
7 |
| Major Risk Factors for PAD |
8 |
| Five-Year All-Cause Mortality for PAD with Smoking or CAD Compared to Controls |
9 |
| Guidelines for Total Cholesterol |
10 |
| Guidelines for LDL Cholesterol |
11 |
| Multiple Risk Factors Increase the Risk of PAD |
12 |
| Ankle Brachial Index (ABI) |
13 |
| ABI and PAD— Severity and Symptoms |
14 |
| Estimated Number of People with PAD 2000 |
16 |
| Percentage of the U.S. Population with Diagnosed Diabetes |
16 |
| Percentage of Diabetics and Non-Diabetics with PAD |
17 |
| Estimated Number of People with PAD 2000-2020 |
18 |
| PAD Prevalence Compared to Other Serious Diseases |
18 |
| The MCVI Survey of Primary Care Physicians (PCPs) |
19 |
| PAD and Diabetes Estimated Percentage of Patients Diagnosed |
20 |
| Legs For Life® Screening Results |
21 |
| Treatment of PAD |
21 |
| Risk Factor Modification |
21 |
| Standard Drug Therapy |
23 |
| Pharmaceutical Therapy for Hypertension |
26 |
| ACE Inhibitors |
28 |
| Angiotensin Receptor Blockers (Antagonists) |
29 |
| Antiplatelets |
30 |
| Lipid-Lowering Agents Statins and Cholesterol Absorbtion Inhibitors |
33 |
| Other Lipid-Lowering Agents |
37 |
| Cholesterol Reduction And Vascular Remodeling In The Lower Limbs |
39 |
| Guidelines for HDL Cholesterol |
40 |
Characteristics of Common Dyslipidemia Patterns
In CAD, PAD and Atherogenic/ Diabetic Dyslipidemia |
41 |
| Triglyceride Levels |
41 |
| New Risk Factors |
42 |
| CRP Levels and Heart Attack Risk |
44 |
| Drug Therapy for Claudication Symptoms |
46 |
| Percentage of PAD Patients Needing Treatment |
47 |
| PAD Patients Undertreated in Primary Care Setting |
48 |
| PAD Patients Undertreated Before and After Revascularization At Academic Medical Centers |
48 |
| U.S. PAD Market Potential for Drug Therapy By Therapeutic Category 2000 |
49 |
| U.S. PAD Market Potential For Selected Drug Categories As The Population Ages 2000-2020 |
50 |
| Estimated U.S. Market for Claudication Therapy 2000-2020 |
50 |
| Estimated U.S. Sales of Claudication Drugs And Additional Market Potential 2002 |
51 |
| Estimated U.S. PAD Market for Antihypertensive Therapy 2000-2020 |
52 |
| U.S. Revenues of Selected ACE Inhibitors 2002 |
52 |
| U.S. Revenues of Selected ARBs 2002 |
53 |
| Estimated U.S. ACE and ARB Markets and Additional Market Potential With Treatment of PAD Patients 2002 |
53 |
| Estimated U.S. PAD Market for Antilipids 2000-2020 |
54 |
| U.S. Revenues of Selected Statins 2002 |
55 |
| Estimated U.S. Lipid Reduction Market and Additional Market Potential With Treatment of PAD Patients 2002 |
55 |
| Estimated U.S. PAD Market for Antiplatelet Therapy 2000-2020 56 |
|
| Estimated U.S. Plavix Sales and
Additional Market Potential With Treatment of PAD Patients 2002 |
56 |
| Valuation Tables |
57 |
| Company Financials |
59-82 |
